HER2阳性乳腺癌的多模态影像学综述及其对新辅助化疗的反应
本文综述HER2阳性乳腺癌在乳腺X线、超声和MRI上的初始表现及新辅助化疗后的不同反应,指出乳腺X线钙化与病理结果相关性差,而乳腺MRI表现仍是预测病理反应的最佳指标,并强调影像评估对手术规划的重要性。
要点
- HER2阳性乳腺癌在乳腺X线或超声上多表现为边缘毛刺的不规则肿块,常含钙化;MRI可表现为肿块或非肿块强化。
- 新辅助化疗后,乳腺X线所示钙化与病理分析结果尤其难以对应。
- 乳腺MRI表现仍是预测病理反应的最佳指标。
核心结论
- 影像学在评估HER2阳性乳腺癌局部区域病变范围和新辅助治疗反应中具有重要作用,可影响手术规划和辅助治疗决策;但治疗反应的评估仍然困难,不同影像模态与手术病理分析相比可能不同程度地低估或高估病变。
研究设计与样本
- 多模态影像学综述,结合病理对照,回顾HER2阳性肿瘤的初始表现、对新辅助化疗的不同反应以及评估残留癌负荷的挑战。
关键影像表现/征象
- HER2阳性乳腺癌在乳腺X线或超声上最常见的表现为边缘毛刺的不规则肿块,常含钙化。
- 在MRI上,HER2阳性乳腺癌可表现为肿块或非肿块强化。
- 组织病理学分析中HER2阳性乳腺癌常为中至高级别核级。
诊断标准与关键数值
- 乳腺X线所示钙化的存在与化疗后病理分析结果尤其难以对应。
- 乳腺MRI表现仍是预测病理反应的最佳指标。
临床应用与阅片要点
- 影像评估局部区域病变范围和新辅助治疗反应,可为手术规划和辅助治疗提供信息。
- 不同影像模态与手术病理分析相比可能不同程度地低估或高估病变。
- 乳腺X线所示钙化与化疗后病理分析结果尤其难以对应。
局限性
- 治疗反应的评估仍然困难,不同影像模态与手术病理分析相比可能不同程度地低估或高估病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Human epidermal growth factor receptor 2 (HER2/neu or ErbB2)-positive breast cancers comprise 15%-20% of all breast cancers. The most common manifestation of HER2-positive breast cancer at mammography or US is an irregular mass with spiculated margins that often contains calcifications; at MRI, HER2-positive breast cancer may appear as a mass or as nonmass enhancement. HER2-positive breast cancers are often of intermediate to high nuclear grade at histopathologic analysis, with increased risk of local recurrence and metastases and poorer overall prognosis. However, treatment with targeted monoclonal antibody therapies such as trastuzumab and pertuzumab provides better local-regional control and leads to improved survival outcome. With neoadjuvant treatments, including monoclonal antibodies, taxanes, and anthracyclines, women are now potentially able to undergo breast conservation therapy and sentinel lymph node biopsy versus mastectomy and axillary lymph node dissection. Thus, the radiologist's role in assessing the extent of local-regional disease and response to neoadjuvant treatment at imaging is important to inform surgical planning and adjuvant treatment. However, assessment of treatment response remains difficult, with the potential for different imaging modalities to result in underestimation or overestimation of disease to varying degrees when compared with surgical pathologic analysis. In particular, the presence of calcifications at mammography is especially difficult to correlate with the results of pathologic analysis after chemotherapy. Breast MRI findings remain the best predictor of pathologic response. The authors review the initial manifestations of HER2-positive tumors, the varied responses to neoadjuvant chemotherapy, and the challenges in assessing residual cancer burden through a multimodality imaging review with pathologic correlation. © RSNA, 2023 Quiz questions for this article are available through the Online Learning Center.
引用
- Portnow LH, Kochkodan-Self JM, Maduram A, et al. Multimodality Imaging Review of HER2-positive Breast Cancer and Response to Neoadjuvant Chemotherapy. Radiographics. 2023. PMID: 36633970. doi:10.1148/rg.220103
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。